Navigation Links
New Drug May Offer Hope to Some With Lung Cancer
Date:9/19/2009

Pemetrexed improves survival with advanced non-small-cell tumors, study finds,,

SATURDAY, Sept. 19 (HealthDay News) -- Maintenance therapy with the drug pemetrexed improves the survival of people with non-small-cell lung cancer whose disease has not progressed after chemotherapy, a new study has found.

Nearly 90 percent of all people who die from lung cancer have non-small-cell tumors. At the time the cancer is discovered, it's considered advanced about 40 percent of the time, according to background information in a news release from The Lancet, which is publishing the study. Chemotherapy reduces the tumors in just 40 percent of advanced cases, it said.

The phase 3 study included 663 people in 20 countries who had an advanced stage of the cancer but no disease progression after four cycles of platinum-based chemotherapy. They were randomly selected to be given pemetrexed or a placebo in 21-day cycles.

The cancers did not progress for 4.3 months, on average, in people in the pemetrexed group, compared with 2.6 months in the placebo group, the study found. People given pemetrexed survived an average of 13.4 months, compared with 10.6 months for those given the placebo.

That means that those in the pemetrexed group had a 50 percent reduction in the risk for disease progression or death and a 21 percent reduction in the risk of death only, the researchers said.

Drug-related toxic effects caused discontinuation of treatment in 5 percent of the pemetrexed group and 4 percent of the placebo group. No deaths were found to be related to pemetrexed, according to the study.

"Pemetrexed maintenance therapy is well tolerated and offers significantly improved progression-free and overall survival compared with placebo, making it a new treatment option for patients with advanced non-squamous, non-small-cell lung cancer who do not progress after initial induction therapy," Dr. Chandra Belani, of the Penn State Hershey Cancer Institute, and her colleagues concluded.

The study, which appears online and in an upcoming print issue of The Lancet, was released Sept. 19 to coincide with the European Cancer Organization meeting.

Dr. Thomas Stinchcombe of the Lineberger Comprehensive Cancer Center at the University of North Carolina, and Dr. Howard West, of the Swedish Cancer Institute in Seattle, wrote in an accompanying editorial that the use of pemetrexed as maintenance therapy "merits being considered as a strong option, reflected by the recent approval of pemetrexed in this setting by the European Medicines Agency and the U.S. Food and Drug Administration."

More information

The American Cancer Society has more about non-small-cell lung cancer.



-- Robert Preidt



SOURCE: The Lancet, news release, Sept. 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Health care incentive model offers collaborative approach
3. Eye-staining technique offers early detection for dry eye syndrome
4. Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Psoriasis Cure Now offers Back to School Resources for Parents of Children with Psoriasis
7. ADDAS Awareness Campaign Offers Resources and Education to Adults Living with AD/HD and Professionals Working With Them
8. Consumers Offer to Pay More to Satisfy Health Demands
9. Regence Offers InterM to Fill Gap for the Uninsured
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Experimental Antidepressants Offer Faster Relief
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug May Offer Hope to Some With Lung Cancer
(Date:5/31/2016)... ... May 31, 2016 , ... Splashtop Inc., the worldwide leader ... with e-Jan Networks Co., the leading provider of secure mobile remote access solution ... Networks’s leading CACHATTO remote access solution. Splashtop for CACHATTO will be ...
(Date:5/31/2016)... ... May 31, 2016 , ... DDL, Inc. announced today ... for Laboratory Accreditation (A2LA) to include ISO 594-1 and ISO 594-2 testing for conical ... achieving a leak-free connection between two medical devices (e.g. a syringe and hypodermic needle) ...
(Date:5/31/2016)... ... , ... Like jewels in a crown, the multiple awards presented to Fayez ... Ontario’s leading day spa and one of Canada’s few accredited 5 Star Spas! ... to combine spa services with hair and beauty services and has resulted ...
(Date:5/31/2016)... ... 31, 2016 , ... The Orthopaedic Research and Education Foundation (OREF) is pleased ... Lewallen, MD, began his term as president in March, succeeding John J. Callaghan, MD, ... new president-elect. Richard F. Kyle, MD, will serve as chair, corporate development, succeeding Thomas ...
(Date:5/31/2016)... ... May 31, 2016 , ... MinerEye today announced ... Security Infrastructure Protection report by Gartner1 Inc. , Each year, Gartner identifies new ... evaluating these innovative vendors and their products and services. , According to Gartner, ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... May 31, 2016 PaperHive ... Content From Elsevier,s ScienceDirect Database ... and medical information products and services, today announced ... -based scientific collaboration platform PaperHive to enable researchers to ... million articles on ScienceDirect , the world,s ...
(Date:5/31/2016)... OXFORD, England , May 31, 2016 ... increasing global demand for its Patient Status Engine wireless patient ... India , Germany , ... , The company,s 2 nd generation system, launched earlier ... around the world , , This new ...
(Date:5/30/2016)... May 30, 2016 Transparency Market ... (3D/4D) Visualization Systems Market - Global Industry Analysis, Size, ... to the report, the global advanced (3D/4D) visualization systems ... and is anticipated to expand at a CAGR of ... Bn in 2024. Advanced (3D/4D) visualization systems ...
Breaking Medicine Technology: